what is known already: Non-obese women with PCOS who conceived spontaneously have a significantly reduced placental volume and weight, with more chronic villitis and intervillositis compared with healthy controls. study design, size, duration: A subset of a large prospective cohort study of pregnant women with PCOS was used. Healthy (low-risk) women who delivered at term after an uncomplicated pregnancy were used as the reference population. The placentas of 73 women with PCOS were analysed and compared with 209 placentas of healthy women.
Introduction
Polycystic ovary syndrome (PCOS) is a common condition in women of reproductive age, characterized by anovulatory infertility, obesity and metabolic abnormalities, such as dyslipidaemia and insulin resistance . Women with anovulatory PCOS are often treated with clomiphene citrate or FSH to induce ovulation, resulting in a pregnancy in almost 80% of women within 2 years (Veltman-Verhulst et al., 2012) .
Women with PCOS who achieve a pregnancy are at increased risk of complications, including pregnancy-induced hypertension (PIH), preeclampsia (PE), gestational diabetes (GDM) and preterm delivery (Boomsma et al., 2006; Kjerulff et al., 2011; Qin et al., 2013) . The placenta is suggested to play a key role in the development of these pregnancy complications, especially of hypertensive pregnancy complications, such as PIH and PE (Redman and Sargent, 2005; Longtine and Nelson, 2011) . It is thought that early placental development in PCOS is aberrant, because of the common metabolic abnormalities that characterize PCOS (e.g. insulin resistance) along with the hyperandrogenic state associated with PCOS (Palomba et al., 2012 (Palomba et al., , 2015 . Obesity is another common feature among women with PCOS, which is known to induce an inflammatory response in the placenta and is associated with pathological lesions (Huang et al., 2014; Jeve et al., 2014) . The most common pregnancy complication in women with PCOS is GDM (de Wilde et al., 2014) . As previously demonstrated, placentas of women without PCOS, who developed GDM show significantly increased villous immaturity, villous necrosis, chorangiosis, ischaemia and nucleated red blood cells (nRBCs) compared with women without GDM (Daskalakis et al., 2008; Madazli et al., 2008) .
Based on the distinctive metabolic profile of women with PCOS on the one hand, and the fact that these women more often develop pregnancy complications on the other hand, we hypothesize that placentas of women with PCOS may be morphologically different from placentas of women without PCOS. Currently, only one case-control study has been performed to compare the characteristics of placentas of women with and without PCOS. In that particular study it was observed that placentas of women with PCOS were significantly thinner, with a reduced volume and lower weight compared with women without PCOS, with significantly more chronic villitis and intervillositis (Palomba et al., 2013) . However, this study only included a selected group of women with PCOS who were non-obese, conceived spontaneously and did not develop any pregnancy complications. This cohort therefore does not represent the full spectrum of the heterogeneous PCOS population.
The aim of our study was to compare macroscopic and microscopic placental characteristics between a heterogeneous, unselected group of pregnant women with PCOS and a reference group of low-risk pregnancies from the general population. Furthermore, within the PCOS group, the placental characteristics of hyperandrogenic and non-hyperandrogenic women were compared and of women with pregnancy complications were compared with those of women without complications.
Materials and Methods

Design
For this study, a subset of the CoPPer study (Complications of PCOS Pregnancy: Evaluating risk), a large prospective multi-centre study from the Netherlands, was used. Between April 2008 and April 2012, women diagnosed with PCOS and a wish to conceive were included in this study prior to conception. PCOS was diagnosed according to the Rotterdam 2003 consensus criteria following standardized phenotyping (Rotterdam ESHRE/ ASRM-Sponsored PCOS Consensus Workshop Group, 2004; Goverde et al., 2009) . Women younger than 18 years or older than 45 years, with a language barrier or with pre-existing diabetes mellitus were excluded in the CoPPer study. Placentas were collected from all women who delivered a singleton neonate at the University Medical Centre Utrecht (UMCU), and these data were used for the current study.
As a reference group, data from women who delivered at term after an uncomplicated pregnancy were used. These women had a spontaneous onset of labour and delivered at home or in the hospital or these women had a benign indication for a primary Caesarean section (i.e. breech position of the fetus, repeat Caesarean section) which was performed in the Diakonessenhuis in Utrecht.
The design and clinical assessments of both studies are extensively described elsewhere (Houben et al., 2009; de Wilde et al., 2014) . All women received antenatal care according to standard Dutch pregnancy protocols. For women with PCOS who participated in the CoPPer study, androgens (i.e. testosterone, sex hormone binding globulin (SHBG)) were measured prior to conception. Hyperandrogenism was defined as a free androgen index (FAI; SHBG/testosterone × 100) ≥ 4.5. Moreover, all women with PCOS underwent an oral glucose tolerance test (100-g glucose load, 3 h follow-up) at 24-26 weeks of pregnancy.
Ethical approval
This study has been approved by the institutional review board of the UMC Utrecht. All women who participated gave written informed consent.
Pregnancy outcomes
Pregnancy outcome data were collected by a medical doctor or a midwife after delivery. GDM was defined as two or more plasma glucose levels exceeding a given threshold after a 100-g glucose load: fasting glucose ≥5.3 mmol/l, 1 h glucose ≥10.0 mmol/l, 2 h glucose ≥8.6 mmol/l, 3 h glucose ≥7.8 mmol/l. PIH was defined as a systolic blood pressure ≥140 mmHg and/or a diastolic blood pressure ≥90 mmHg. PE was defined as PIH and proteinuria (≥300 mg/24 h). Large for gestational age (LGA) was defined as infant birthweight above the 90th percentile and small for gestational age (SGA) was defined as infant birthweight below the 10th percentile, adjusted for gestational age, gender and parity, according to the most recent growth charts used in the Netherlands ).
Placenta examination
After delivery, placentas were stored at +48C and processed within 72 h in the UMCU. An experienced pathologist (PN), blinded for clinical data, performed macroscopic and microscopic analyses of the placentas. The placentas were weighed without umbilical cord and membranes. Samples of the insertion of the umbilical cord as well as samples randomly taken from the centre of a cotyledon in the parenchyma were collected for histological examination and additional samples were taken randomly from macroscopically abnormal parenchyma (e.g. change of colour or consistency and/or the presence of white or red nodular lesions). All samples were embedded in paraffin and stained with standard haematoxylin and eosin (H&E) and histopathological observations were performed according to the Redline criteria (Redline, 2008) . Placental weight, without umbilical cord and membranes, was determined and the ratio between the infant's birthweight and placental weight was calculated.
Chronic inflammation of membranes was defined as the presence of groups of more than 50 lymphocytes and/or plasma cells in the membranes at a 10 times microscopy magnification. Laminar necrosis of membranes was defined as the presence of a coagulative necrotic area in the decidua. Chorioamnionitis was defined as the presence of neutrophilic granulocytes in the chorionic plate and/or the extraplacental membranes (amnion); funisitis was defined as the presence of neutrophils in the wall of the umbilical vein and/or arteries. Chronic villitis was defined as an infiltration of lymphocytes and macrophages in groups of at least five placental villi. The presence of nRBCs was documented with the occasional presence of NRBC in umbilical cord blood or abundant presence in terminal villi. Villous immaturity was defined as a delay in the formation of syncytiocapillary membranes (SCM) in terminal villi and was determined as previously described (de Laat et al., 2007) . A SCM was defined as a dilated capillary in broad contact with the thin trophoblastic cover, without presence of a nucleus in the contact area according to Stallmach et al. (2001) . Formation of SCM or maturation was classified as abnormal if in at least one slide the mean of SCM was less than 0.25 SCM/villus in the 10 smallest villi in 10 fields. Fetal thrombosis was determined as groups of at least five avascular fibrotic villi, thrombosis in a vessel of the umbilical cord, chorionic plate or stemvillus, haemorrhagic endovasculitis, or intramural deposition of fibrin in a vessel of the umbilical cord, chorionic plate or stemvillus; infarction was defined as microscopically proven macroscopical lesions; and ischaemia was defined as the presence of hyperchromasia of trophoblast and Tenney-Parker changes.
Statistical analysis
All baseline and pregnancy outcome characteristics were presented as means with standard deviations (SD) for continuous data and as numbers with percentages for categorical data. All data refer to the number of patients in our study. To analyse differences among these characteristics between women with and without PCOS, Student's t-tests and Chi-square tests were used.
To analyse differences in placental characteristics between groups, multivariate logistic regression analysis was used with placental characteristics as dependent and PCOS as independent variable. P-values were subsequently adjusted for potential confounders or effect modifiers. Primarily, we adjusted for baseline variables, i.e. maternal age, ethnicity, nulliparity and smoking. Secondly, we adjusted for outcome variables as well, i.e. gestational age at delivery, mode of delivery and the presence of pregnancy complications.
To study whether placental characteristics were associated with common features of PCOS, such as obesity (BMI ≥ 30) or hyperandrogenism, Chi-square tests were performed. Since we did not possess data on BMI and androgens in the reference group, this analysis was only performed within the group of women with PCOS.
Also within the PCOS group, a subgroup analysis was performed in which placental characteristics were compared between women with and without pregnancy complications (divided in PIH or PE and GDM). F-tests or likelihood ratio tests for a model with any pregnancy complications versus without were used to determine whether these pregnancy complications had any influence on the placental characteristics studied.
P-values ,0.05 were considered statistically significant. All statistical analyses were performed using the Statistical Package for Social Sciences (IBM SPSS, Inc., Chicago, IL, USA, version 21.0).
Results
A total of 73 women with PCOS were included in the study as well as 209 women from a low-risk reference group. Table I shows the pregnancy characteristics of the women in both groups. Women in the PCOS group were more often Caucasian (95 versus 73%; P , 0.001), more often nulliparous (81 versus 40%; P , 0.001) compared with women in the control group. Smoking was less common in women with PCOS (1 versus 12%; P , 0.001) compared with the control group. Pregnancy complications were more frequent among women with PCOS; 14% of women were diagnosed with PIH or PE and 29% of women had GDM compared with 5% and 1% in the reference group, respectively. Table II shows the placental characteristics of both groups. We observed more chronic inflammation of fetal membranes in the reference group compared with women with PCOS, but this difference was no longer significant after adjustment for potential confounding variables. After adjustment for potential confounders, we found more often chorioamnionitis (30 versus 10%; P , 0.001), funisitis (8 versus 1%; P ¼ 0.019), villitis (19 versus 13%; P ¼ 0.045), thrombosis (13 versus 5%; P ¼ 0.018), infarction (16 versus 6%; P ¼ 0.010), villous immaturity (41 versus 23%; P ¼ 0.009) and nRBCs (47 versus 16%; P , 0.001) in placentas from women with PCOS compared with controls (Table II) . Histological images of typical placental findings in women with PCOS with and without pregnancy complications are shown in Fig. 1 .
Women with a hyperandrogenic PCOS phenotype (n ¼ 34; 47%) had a lower fetal-to-placental weight ratio compared with nonhyperandrogenic women (ratio 6.6 versus ratio 7.3), but this was not statistically significant after adjustment for potential confounders. Moreover, villous immaturity was less often present in hyperandrogenic compared with non-hyperandrogenic women with PCOS (27 versus 54%; P ¼ 0.037). We found no associations between placental characteristics and obesity (n ¼ 16; 22%) in our PCOS population.
In a subgroup analysis within the PCOS group, we observed a slightly lower fetal-to-placental weight ratio among women who experiences PIH or PE (ratio 6.7) and GDM (ratio 6.9) compared with the reference group (ratio 7.1), although this difference was not statistically significant. The occurrence of villitis was increased in uncomplicated pregnancies (27%, versus 0% in PIH or PE pregnancies and 10% in GDM pregnancies; P ¼ 0.037) and the occurrence of thrombosis was increased in PIH or PE pregnancies (30%, versus 0% in GDM pregnancies and 13% in uncomplicated pregnancies; P ¼ 0.008). While there were no significant differences in villous immaturity and the amount of nRBCs between the three subgroups, the occurrence of these parameters was rather high within all these groups (Table III) .
Discussion
The current study compared macroscopic and microscopic placental characteristics between women with PCOS and women of a healthy, low-risk reference group. Furthermore, a sub-analysis was performed among women with PCOS to compare placentas after either an uncomplicated pregnancy or a pregnancy complicated by PIH, PE or GDM. After adjustment for potential confounding variables, placentas from women with PCOS showed a significantly increased prevalence of several histopathological abnormalities compared with the reference group, which is in accordance with a previous study in women with PCOS (Palomba et al., 2013) . Most of these differences could not be explained by an increased incidence of pregnancy complications in women with PCOS; only villitis and thrombosis were different among these groups.
In the current study, placentas of women with PCOS showed signs of increased placental inflammation, such as common presence of chorioamnionitis, funisitis and villitis, when compared with our reference group. Placental inflammation has previously been related to the presence of pregnancy complications Mrizak et al., 2014; Staff et al., 2014; Veerbeek et al., 2014) as well as to maternal obesity (Challier et al., 2008; Denison et al., 2010; Zhu et al., 2010) , both of which are more prevalent in women in PCOS. In our PCOS population, mean maternal BMI was 26 kg/m 2 and 22% of the women had a BMI ≥ 30 kg/m 2 . Unfortunately, we did not have data on maternal BMI of our reference group, but in the Dutch female population the prevalence of obesity (defined as BMI ≥ 30 kg/m 2 ) is 10-15% (Schokker et al., 2007; World Health Organization, 2013) . This difference in BMI may partially explain our findings of more placental inflammation. Within our PCOS population, we did not observe any associations between placental characteristics and obesity. However, obesity is known to worsen PCOS features and therefore probably also placental characteristics, but since our PCOS population is relatively lean, it might be that differences are just too small to be statistically significant. In addition to altered inflammatory features, placentas of women with PCOS more often showed thrombosis and infarction. These may reflect signs of vascular damage and fetal hypoxia, which are common to a number of pregnancy complications, such as PE and fetal growth restriction (Salafia et al., 1995; Sikkema et al., 2002; Veerbeek et al., 2014) . In our study, we did not observe any differences in infant birthweight, nor in the presence of SGA infants between the PCOS and the reference group. We did, however, find an increased incidence of PIH/PE in women with PCOS (Table II) , which could possibly explain the increased presence of placental thrombosis and infarction in these women. Yet, even in women with PCOS who had an uncomplicated pregnancy, the prevalence of placental thrombosis and infarction was high compared with our reference group (13% versus 5% for thrombosis and 16% versus 6% for infarction, respectively).
Another possible sign of relative placental hypoxia is the higher incidence of villous immaturity and nucleated fetal red blood cells (nRBCs) in women with PCOS. This may be explained by exposure of the placenta to high levels of nutrients, in particular in mothers who develop GDM, have obesity or gain excessive weight in pregnancy, which leads to accelerated growth of placental villi resulting in relative villous immaturity (Redline, 2008) . As a consequence, the distance between the intervillous space and the fetal capillaries increases, which can result in chronic fetal hypoxia (Laurini et al., 1987) , and the presence of nRBCs in the placenta (Korst et al., 1996) . Fortunately, we did not observe an increased incidence of fetal asphyxia in our study, although this may be due to the generally low incidence of asphyxia in relation to the sample size of our PCOS cohort.
Earlier studies have shown that placentas of women with diabetes show significantly more often signs of villous immaturity and that they tend to have higher weights in order to compensate for the hypoxia by increasing the area of oxygen exchange (Evers et al., 2003; Daskalakis et al., 2008; Higgins et al., 2012) . Thus, one might expect a higher prevalence of villous immaturity and nRBCs in women with PCOS, since obesity and GDM are commonly present in this group (Kjerulff et al., 2011; Fauser et al., 2012) . However, even after adjustment for pregnancy complications, such as GDM, the differences between women with PCOS and the reference group remained statistically significant in our study. Data are expressed as mean + SD or n (%). PCOS, polycystic ovary syndrome; PIH/PE, pregnancy-induced hypertension or pre-eclampsia; C-section, Caesarean section.
are metabolically disturbed-presumably related to hyperandrogenism and insulin resistance-which could result in placental alterations comparable to those observed in GDM. This has also been suggested in a previous study in which it was demonstrated that microscopic placental alterations are significantly influenced by the FAI and homostatic model assessment of insulin resistance (HOMA-IR) (Palomba et al., 2013) . In our study, we also found an association between FAI and villous immaturity. Hyperandrogenism has been shown to inhibit placental growth in rats (Sun et al., 2012) and has been suggested to impair trophoblast invasion in humans (Palomba et al., 2012) . If this is indeed true, hyperandrogenism may also play a role in the increased prevalence of placental features related to hypoxia, although future research should clarify its exact underlying pathways.
A limitation of the current study is that women in the reference group were not screened for PCOS. We did have information on whether or not women in the reference group conceived spontaneously, but there may still have been some women with PCOS in the control group who conceived naturally. If this would indeed be true, it may be anticipated Data are expressed as mean + SD or n (%). PCOS, polycystic ovary syndrome; PIH/PE, pregnancy-induced hypertension or pre-eclampsia; GDM, gestational diabetes. *P-value adjusted for maternal age, ethnicity, nulliparity and smoking. **P-value adjusted for maternal age, ethnicity, nulliparity, smoking, PIH/PE, GDM, gestational age at delivery and mode of delivery. ***Fetal membranes were not examined in 81 placentas from the reference group.
that the differences in placental characteristics will be even more pronounced comparing women with and without PCOS. Moreover, some placentas, which were stored at 48C may have been subjected to a relatively long interval between delivery and fixation (max 72 h). However, the markers used in our scoring system are very robust and have extensively been validated and used for many years in standard operating procedure protocols without any obvious problems with tissue deterioration. Although we expect no major problems to have occurred due to possible delayed fixation in our study, some degenerative changes cannot be ruled out absolutely. Also, we cannot rule out the possibility that other baseline differences between women with PCOS and the reference group may in part explain some of the observed differences in placental pathology. Firstly, women with PCOS more often smoked during pregnancy compared with the reference group, which could enhance the prevalence of placenta pathology. Secondly, our PCOS group was recruited for participation in scientific research and it is known that this may induce bias, especially regarding ethnicity and socioeconomic status. Thirdly, our reference group was recruited from primary obstetrical care practices (Houben et al., 2009 ). In the Netherlands, women who are at increased risk of pregnancy complications (i.e. GDM or PE) are referred to a gynaecologist (secondary obstetrical care). Thus, our reference group consisted only of healthy women with hardly any pregnancy complications. Yet, in the reference group, a substantial number of women who underwent a primary Caesarean section were included (19%). It is known that placental inflammation is a physiological response in labour and delivery (Salafia et al., 1989) , which is less present in placentas from women who underwent a primary Caesarean section (Houben et al., 2009) . Because of these differences between our study groups, analyses were adjusted for baseline characteristics and pregnancy complications, to prevent any confounding or effect modification.
In conclusion, women with PCOS have significantly more inflammatory and thrombotic lesions as well as increased villous immaturity of the placenta compared with women from a reference group, which seems not to be caused by the higher incidence of pregnancy complications in women with PCOS. Further research is needed to explore possible causes of placental alterations in women with PCOS and its possible implications for clinical practice. 
